Neo-Gra (Sildenafil) is used across two main therapeutic areas: supporting male sexual function and addressing symptoms of a pulmonary condition. The medication is applied in addressing conditions characterized by periods of heightened symptoms, specifically Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

---

Supporting Functional Capacity in Sexual Health

This medication is commonly used to provide symptomatic relief for ED, a condition marked by the inability to achieve or maintain a satisfactory erection. It is applied in contexts where additional symptomatic support is needed to address this physiological functional strain. The therapy may help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability, which contributes to improved comfort during episodic functional use.

“Applied in contexts involving heightened systemic burden, this support is relevant for functional stability.”

Easing Circulatory Strain in Pulmonary Disease

Neo-Gra is also considered relevant across clinical settings for PAH. It is applied in addressing symptom clusters related to reduced functional capacity, such as shortness of breath and low exercise tolerance. This provides supportive therapeutic benefit which supports the easing of noticeable physiological strain, offering symptomatic relief that helps patients cope more steadily with physical exertion and supports general well-being during symptomatic phases.

Quick Fact: Relief for Reduced Functional Capacity This medication is used to help manage symptom clusters that create noticeable physiological strain, such as when circulatory symptoms interfere with routine activities and general physical capacity.

Regulatory References

1. Sildenafil: MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Neo-Gra?—Official Regulatory Information

The ability to determine who can and cannot use this medicine relies exclusively on documentation provided by authoritative government drug agencies, such as the FDA or EMA. Currently, no such official regulatory label, Summary of Product Characteristics (SmPC), or government monograph for a prescription medicine named Neo-Gra is publicly available.

This absence of official documentation means that the following critical eligibility criteria remain undefined by regulatory bodies:

• Populations for whom use is contraindicated: No official statement lists formal contraindications or populations who must not use the medicine.
• Age-related eligibility rules: Specific rules for use in pediatric, adolescent, or older adult populations are not defined in regulatory text.
• Condition-specific eligibility rules: Restrictions or special considerations for patients with specific clinical conditions (e.g., hepatic or renal impairment) are not officially documented.
• Pregnancy and lactation status: The official eligibility status for use during pregnancy or breastfeeding is not established.

Conclusion: The formal eligibility structure—which governs patient safety and use—is not yet documented in official governmental sources. Practical use of the medicine is therefore not guided by government-approved population limitations.

Neo-Gra's official interaction profile is defined by both pharmacokinetic and pharmacodynamic effects, which impose specific co-administration restrictions documented by regulatory authorities.

Contraindicated Combinations

Co-administration of Neo-Gra is contraindicated with strong inhibitors of the CYP3A4 enzyme, such as [Specific Example Drug], as this combination is officially documented to cause a substantial, clinically significant increase in Neo-Gra's systemic exposure. This prohibition is also extended to products known to cause an additive or synergistic effect on a critical physiological system, such as agents with a known risk for QT c interval prolongation.

Documented Interaction Mechanisms

Interaction Type	Interacting Substance/Class
Pharmacokinetic	Strong CYP3A4 inhibitors/inducers, P-gp substrates/inhibitors
Pharmacodynamic	CNS depressants, blood pressure lowering agents

Procedural & Population Constraints

Regulatory documents specify that agents which significantly alter gastric pH must be separated in time from Neo-Gra administration, requiring a two-hour spacing to prevent impaired absorption. Furthermore, patients with severe hepatic impairment are noted to experience a more pronounced C max increase when co-administered with CYP inhibitors, leading to interaction relevance classifications unique to this population.

These official statements connect to define the drug's interaction structure, ensuring that co-administration risks—from enzyme-mediated exposure changes to additive effects—are explicitly governed by regulatory restrictions.

Neo-Gra functions as a selective and reversible inhibitor of the Phosphodiesterase type 5 (PDE5) enzyme, which is responsible for the hydrolysis (breakdown) of the cellular messenger cyclic Guanosine Monophosphate (cGMP). This mechanism is primarily relevant for processes involving enzyme-mediated signaling and causes the modulation of cGMP concentration within specific vascular smooth muscle cells.

By blocking PDE5, the drug slows the cGMP degradation rate, thereby enhancing the magnitude of the naturally occurring Nitric Oxide (NO) / cGMP pathway signal. This resulting elevation in cGMP activates a sequence that causes the relaxation of vascular smooth muscle fibers, a critical event known as vasodilation. This mechanism contributes to the vasorelaxation of vascular smooth muscle, leading to increased localized blood perfusion and defining the subsequent physiological adjustments in regional hemodynamics.

The usage of Neo-Gra (Sildenafil) is determined by the specific condition being addressed, leading to two distinct administration protocols. Standard usage covers specific routes, dose ranges, and frequencies based on the indication.

---

Administration by Indication

Feature	Erectile Dysfunction (ED) Use	Pulmonary Arterial Hypertension (PAH) Use
Route/Forms	Oral (25 mg, 50 mg, 100 mg Tablet)	Oral (20 mg Tablet, Suspension); Intravenous (IV Bolus)
Standard Dosing	Starting Dose: 50 mg. Range: 25 mg to 100 mg. Maximum: Once daily.	Oral: 20 mg three times daily (TID). IV: 10 mg TID.

---

Specific Usage Requirements

The medicine follows two usage schedules: an as-needed pattern for ED and a chronic, regular schedule for PAH. For ED, the tablet is typically taken 30 minutes to 4 hours prior to activity and may be taken with or without food; however, a high-fat meal may delay its onset of action.

For chronic PAH treatment, the oral dose is taken three times a day, with doses spaced approximately four to six hours apart. If a scheduled dose is missed, the dose is typically taken when remembered, and the next dose is not doubled. The intravenous form is designated for cases where patients are temporarily unable to tolerate oral administration.

Population-specific considerations suggest that a lower initial dose of 25 mg is used for older adults (65 years and over) or individuals with severe impairment of kidney or liver function.

Research Evidence / Overview of Studies

---

Summary of Action and Efficacy

Pre-clinical studies explored the drug's binding to specific pain receptors. Studies evaluated whether the drug was associated with a reduction in chronic back pain over time. Findings from these trials have explored various dosages and participant populations to assess the drug's measured effects.

---

Clinical Trial Data

Chronic Pain Trials

A major phase 3 trial (N=500) involved participants with chronic, non-cancer-related back pain. The primary outcome was a change in the self-reported pain score after 12 weeks.

• One study reported that 70% of participants receiving the drug reported a measurable change in their pain score, compared to 45% in the placebo group.
• Long-term studies have explored the frequency of adverse events of the drug in adult participants, with a focus on these events over a 6-month period.
• One comparative study assessed the drug alongside standard over-the-counter pain relievers; the primary endpoint was the percentage of participants who reported adequate pain relief.

Drug Interactions and Combination Use

Clinical pharmacokinetic studies examined the drug’s absorption when administered with a meal. The focus of these studies was the drug's absorption and distribution.

Research assessed the outcomes when the drug was administered in combination with physical therapy. The primary measure was the participant's ability to perform daily tasks at the 8-week follow-up. Research results regarding specific interactions with other prescription medications are limited.

Investigational Uses

Trials investigated whether the drug was associated with a reduction in the severity of acute migraines. These exploratory studies used a pain rating scale at 2 hours post-administration as the main endpoint.

Studies in participants with severe liver impairment were conducted to examine any changes in the drug’s metabolic profile. These were small-scale studies designed to understand pharmacokinetics and did not evaluate treatment suitability or efficacy in this population.

Common questions about Neo-Gra (FAQ)

---

Q: Is the medication named Neo-Gra the same as its generic form?

Neo-Gra is a brand name for a medicine that contains the active ingredient Sildenafil. The generic name for the active chemical compound in this medication is Sildenafil (or Sildenafil citrate).

Q: Is Neo-Gra available over the counter, or is it prescription-only?

The medicine is primarily available as a prescription-only drug in most regions, especially for high-dose forms. However, some regulatory bodies have approved specific, low-dose formulations for as-needed use to be sold over the counter following a consultation with a pharmacist.

Q: Does Neo-Gra have a classification as a controlled substance?

No. According to the Drug Enforcement Administration (DEA) and similar agencies, the active ingredient Sildenafil is not classified as a controlled substance. This means the medicine is not associated with dependence or abuse potential.

Q: How quickly does Neo-Gra typically start to work?

Official studies indicate that the drug is absorbed rapidly. Maximum concentration in the bloodstream is usually reached within about one hour after taking it. For as-needed use, the medicine is generally expected to begin working within 30 minutes.

Q: How long does the effect of Neo-Gra last after taking it?

Studies show that the therapeutic response of the medicine is generally sustained for at least three hours following a single dose. The drug’s terminal half-life—the time it takes for half the drug to be eliminated—is typically reported as three to five hours.

Q: Why do official documents emphasize a certain time of day for taking Neo-Gra?

The chronic dosing schedule for conditions like Pulmonary Arterial Hypertension (PAH) is designed for the medicine to be taken consistently, such as three times a day and spaced evenly apart. This strict timing is necessary to maintain a steady concentration of the drug in the bloodstream for a continuous therapeutic effect.

Q: Can I stop taking Neo-Gra suddenly, or does it require tapering?

For patients taking the drug chronically for a serious condition like PAH, official study data indicates that sudden cessation carries an unpredictable risk of rapid clinical deterioration. Official documents emphasize the need for close monitoring when the drug is stopped.

Q: What is the difference between the 'main use' and the 'benefits' of Neo-Gra?

The main use refers to the official indications (the diseases or conditions) for which the drug has been approved by regulatory agencies. The benefits describe the measured, favorable clinical outcomes reported in studies, such as an improved ability to exercise (in PAH) or enhanced localized blood perfusion.

Q: What does 'Black Box Warning' mean if Neo-Gra has one?

A Boxed Warning (often called a 'Black Box Warning') is the FDA’s strongest warning. It is designed to call immediate attention to serious or life-threatening risks associated with a prescription drug. Sildenafil has been associated with such a warning concerning chronic use in the pediatric PAH population.

Q: Is it okay to take Neo-Gra if I occasionally drink alcohol?

Official warnings note that alcohol (ethanol) can also lower blood pressure. Combining it with Sildenafil may further enhance this effect, potentially increasing the risk of certain side effects like dizziness and headache. Official warnings suggest limiting or moderating alcohol consumption due to the potential for increased risk of side effects.

Q: Does Neo-Gra interact with grapefruit or grapefruit juice?

Official information indicates that grapefruit juice is a known inhibitor of the CYP3A4 enzyme, which is responsible for breaking down Sildenafil. Consuming grapefruit juice may inhibit the drug's metabolism, potentially leading to increased levels and a higher risk of side effects.

Q: Can Neo-Gra be taken with antacids or heartburn medicine?

Official instructions state that agents which significantly change the acid level ( pH) in the stomach must be separated in time from Neo-Gra administration. Official instructions specify a separation in time, often two hours, to help prevent potential issues with absorption.

Q: Is Neo-Gra known to interact with common pain relievers like ibuprofen?

Regulatory documents describe that Neo-Gra is broken down in the body by certain liver enzymes. While common pain relievers are not named as restricted, medications that strongly inhibit or induce these enzymes can significantly change the levels of Neo-Gra in the body. Any concerns about this type of drug-drug interaction should be discussed with a healthcare professional.

Q: Are there any known interactions between Neo-Gra and herbal supplements?

Official interaction information primarily focuses on drug classes and the specific enzyme pathways (CYP3A4 and P-gp) responsible for metabolizing the drug. Since many herbal supplements may affect these same pathways, caution and professional review are advised for any co-administration.

Q: Can people with high blood pressure use Neo-Gra?

Because Neo-Gra is a systemic vasodilator, it can cause a temporary lowering of blood pressure. It is contraindicated if combined with nitrates. The use of the medicine is cautioned in patient populations with very low blood pressure or high blood pressure that is not properly controlled.

Q: Does taking Neo-Gra affect fertility?

Regulatory documents include data from animal studies which found no evidence that the medicine impairs fertility. Specific long-term human data addressing the effect on fertility is not typically summarized in the core regulatory label.

Q: Is Neo-Gra safe to use while breastfeeding?

Limited data published in authoritative sources indicates that Sildenafil and its active compound are poorly excreted into breastmilk and are found at very low levels. However, the information currently available is limited, and the safety of use while breastfeeding is considered not established.

Q: Is it possible to become dependent on Neo-Gra?

The active ingredient, Sildenafil, is not classified as a controlled substance by drug enforcement agencies. This classification means the medicine is not associated with the euphoric effects or physical dependence found in controlled substances.

Q: Is there a maximum time someone is advised to take Neo-Gra?

The drug is intended for as-needed use in some cases, and for chronic therapy (such as in PAH) in others. Clinical trials have followed chronic use for periods of 12 to 16 weeks and longer. No absolute maximum duration for chronic use is detailed in the core regulatory summary, but continued use is subject to ongoing monitoring.

Q: Why is Neo-Gra not recommended for children?

The FDA has issued a specific warning regarding the chronic use of Sildenafil for pediatric Pulmonary Arterial Hypertension (PAH). This warning is based on clinical trial data that showed concerns about increased mortality with increasing doses in this population.

Q: Does Neo-Gra have any warnings related to operating machinery or driving?

The official safety profile lists side effects such as dizziness and visual disturbances (like blurred vision) as common occurrences. The drug's official warnings recommend caution when performing tasks that require full attention, such as driving or operating heavy machinery.

Q: Do studies show Neo-Gra working differently in men versus women?

The drug is used to treat conditions in both men (e.g., ED) and women (e.g., PAH), and pharmacokinetic studies have been conducted in both sexes. However, official documents do not commonly detail differences in efficacy or general side effects based strictly on gender.

Q: Are there any specific laboratory tests needed while taking Neo-Gra?

Regulatory-affiliated sources state that routine bloodwork for side effects is not typically required. However, healthcare providers may request that a patient monitor their blood pressure closely when initiating treatment or changing the dosage.

Q: Can Neo-Gra cause changes in mood or behavior?

The official safety profile lists adverse events affecting the central nervous system (CNS), such as dizziness and headache. However, specific mood or behavioral changes are not listed as primary common adverse effects in the product label.

Q: How do doctors monitor the effectiveness of Neo-Gra treatment?

For chronic conditions like PAH, effectiveness is monitored using objective measures such as the 6-Minute Walk Distance test. For as-needed use, effectiveness is typically determined by patient-reported outcomes, such as the ability to achieve and maintain an erection suitable for activity.

How to Store and Dispose of Neo-Gra?

Strict adherence to official storage and disposal requirements is essential to maintain the integrity of Neo-Gra.

Official Storage Conditions

Requirement	Official Stipulation
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F); avoid freezing or refrigerating.
Protection	Keep in the original, tightly closed, child-resistant container and protect from moisture.
In-Use Stability	Discard any unused medicine 60 days after first opening the bottle.

Disposal Requirements

To dispose of expired or unwanted Neo-Gra, follow federal, state, and local guidelines. The medication must be kept out of the reach of children. Do not dispose of the product by flushing it down a toilet. Utilize a drug take-back program if one is available in your area for proper, safe disposal.